Metformin: Effects on micro and macrovascular complications in type 2 diabetes

Cardiovascular Drugs and Therapy

Volumn 22, Issue 3, 2008, Pages 215-224

  Bailey, Clifford J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Hyperglycaemia; Macrovascular complications; Metformin; Microvascular complications; Type 2 diabetes

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CYTOKINE; GLIBENCLAMIDE; GLYCERYL TRINITRATE; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

ANGINA PECTORIS; ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROTHROMBOSIS; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DATA BASE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIUM; GLUCOSE BLOOD LEVEL; GLYCATION; GLYCEMIC CONTROL; HEALTH CARE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPOGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; LACTIC ACIDOSIS; LEG AMPUTATION; LIPID METABOLISM; METABOLIC REGULATION; MONOCYTE; MONOTHERAPY; MORBIDITY; MORTALITY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SLOW RELEASE FORMULATION; STROKE; SURVIVAL RATE; TASTE DISORDER; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; VASCULAR DISEASE; VASODILATATION; VITAMIN ABSORPTION;

ANIMALS; ATHEROSCLEROSIS; BLOOD GLUCOSE; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; METFORMIN; OXIDATIVE STRESS; TREATMENT OUTCOME;

EID: 48349116165     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-008-6092-0     Document Type: Review

References (99)

1. Bailey CJ, Campbell IW, Chan JCN, et al. Metformin. The gold standard. Chichester: Wiley; 2007. p. 288.
2. Nathan DM, Buse JB, Davidson MB, Heine RJ, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia. 2006;49:1711-21.
3. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65:384-411.
4. Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992;15:755-72.
5. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-9.
6. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs. 1999;58:31-9.
7. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167-74.
8. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Revs. 1998;6:89-130.
9. Howlett HCS, Bailey CJ. Risk-benefit assessment of metformin in type 2 diabetes. Drug Safety. 1999;20:489-503.
10. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. JAMA. 2002;287:2570-81.
11. Eckel RH, G rundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28.
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.
14. th International Diabetes Federation Congress, Paris, 2003.
15. Kao J, Tobis J, McClelland RL, et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol. 2004;93:1347-50.
16. Kahn SE, Haffner SM, Heise MA, Herman WH, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-43.
17. Cleland JGF, Atkin SL. Thiazolidinediones, deadly sins, surrogates and elephants. Lancet. 2007;370:1103-4.
18. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-8.
19. Evans JM, Ogston SA, Emslie-Smith MA, Morris A. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulphonylureas and metformin. Diabetologia. 2006;49:930-6.
20. Nichols GA, Koro CE, Gullion CM, et al. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev. 2005;21:51-7.
21. McAfee AT, Koro C, Landon J, et al. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Safety. 2007;16:711-25.
22. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25:2244-8.
23. Johnson JA, Simpson SH, Toth EL, Majumbar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabetic Med. 2005;22:497-502.
24. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345-51.
25. Masudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583-90.
26. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Br Med J. 2007;335:458-9. DOI 10.1136/bmj.39314.620174.80.
27. Roberts F, Ryan GJ. The safety of metformin in heart failure. Ann Pharmacother. 2007;41:462-6.
28. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. Br Med J. 2003;326:4-5.
29. Inzucchi SE. Metformin and heart failure: innocent until proven guilty. Diabetes Care. 2005;28:2585-7.
30. Holstein A, Stumvoll M. Contraindications can damage your health-is metformin a case in point? Diabetologia. 2005;48:2454-9.
31. Katakami N, Yamaski Y, Hayaishi-Okano R, et al. Metformin and gliclazide rather than glibenclamide attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004;47:1906-13.
32. Matsumoto K, Sera Y, Abbe Y, et al. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Prac. 2004;64:2205-8.
33. Orio F, Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normal weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab. 2005;90:6072-6.
34. Li L, Mamputu JC, Wiernsperger N, Renier G. Signalling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes. 2005;54:2227-34.
35. Sirtori CR, Franceschini G, Gianfranceschi G, et al. Metformin improves peripheral vascular in nonhyperlipidemic patients with arterial disease. J Cardiovasc Pharmacol. 1984;6:914-23.
36. Montaguti U, Cellin D, Ceredi C, Descovitch GC. Efficacy of the long-term administration of metformin in hyperlipidaemic patients. Res Clin Forums. 1979;1:95-103.
37. Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabetic Med. 2003;20:255-68.
38. Sjoholm A, Nystrom T. Endothelial inflammation in insulin resistance. Lancet. 2005;365:610-2.
39. Lyon CJ, Law RE, Hsueh WA. Adiposity, inflammation and atherogenesis. Endocrinology. 2003;144:2195-200.
40. Saenz A, Fernandez-Esteban I, Mataix A et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, 2005, CD002966.
41. Schafers RF. Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes Metab. 2003;29:62-70.
42. Wulffele MG, Kooy A, de Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256:1-14.
43. Lawrence JM, Reid J, Taylor GJ, et al. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care. 2004;27:41-6.
44. Ohira M, Miyashita Y, Ebisuno M, et al. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. Diabetes Res Clin Pract. 2007;78:34-41.
45. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002;25:542-9.
46. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37:1344-50.
47. De Aguiar LG, Bahia LR, Villela N, et al. Metformin improves endothelial vascular reactivity in first degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care. 2006;29:1083-9.
48. Vitale C, Mercuro G, Cornoldi F, et al. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med. 2005;258:250-6.
49. Marfella R, Acampora R, Verrazzo G, et al. Metformin improves hemodynamic and fheological responses to L-arginine in NIDDM patients. Diabetes Care. 1996;19:934-9.
50. Asagami T, Abbasi F, Stuelinger M, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism. 2002;51:843-6.
51. Natale A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004;27:1349-57.
52. Kautzky-Willer A, ra A, Winzer C, et al. Insulin sensitivity during oral glucose tolerance test and its relation to parameters of glucose metabolism and endothelial function in type 2 diabetes subjects under metformin of thiazolidinedione. Diab Obesity Metab. 2006;8:561-7.
53. Carantoni M, Abbasi F, Chu L, et al. Adherence of mononuclear cells to endothelium in vitro is increased in NIDDM. Diabetes Care. 1997;20:1462-6.
54. Mamputu JC, Wiernsperger N, Renier G. Metformin inhibits monocyte adhesion to endothelial cells and foam cell formation. Br J Diabetes Vasc Dis. 2003;3:302-10.
55. De Jager J, Kooy A, Lehert P. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized placebo-controlled trial. J Intern Med. 2005;257:100-9.
56. Skrha J, Praznv M, Milgertova J, et al. Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. Eur J Clin Pharmacol. 2007;63:1107-14.
57. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-74.
58. Carter AM, Bennett CE, Bostock JA, Grant PJ. Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with type 2 diabetes mellitus. Diabetic Med. 2005;22:1282-4.
59. Akbar DH. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Endocrine. 2005;20:215-8.
60. Morin-Papunen L, Rautio K, Ruokonen A, et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:4649-54.
61. Caballero AE, Degado A, Aguillar-Salinas CA, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2004;89:3943-8.
62. Hattori Y, Suzuki K, Hattori S, et al. Metformin inhibits cytokine-induced nuclear factor kappa B activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006;47:1183-8.
63. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597-605.
64. Meifen C, Jie X, Linuo Z, et al. Nonenzymatical glycation of protein in vitro and its inhibition by aminoguanidine or metformin. Acta Acad Med Shanghai. 1998;25:35-8.
65. Beisswenger P, Howell S, Touchette A, et al. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes. 1999;48:198-202.
66. Wiernsperger NF. 50 years later: is metformin a vascular drug with antidiabetic properties? Br J Diabetes Vasc Dis. 2007;7:204-10.
67. Pavlovic D, Kocic R, Kocic G, et al. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obesity Metab. 2000;2:251-6.
68. Ouslimani N, Peynet J, Bonnefont-Rousselot D, et al. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism. 2005;54:829-34.
69. Mahrouf M, Ouslimani N, Peynet J, et al. Metformin reduces angiotensin-mediated intracellular production of reactive oxygen species in endothelial cells through the inhibition of protein kinase C. Biochem Pharmacol. 2006;72:176-83.
70. Onaran I, Guven GS, Ozdas SB, et al. Metformin does not prevent DNA damage in lymphocytes despite its antioxidant properties against cumene hydroperoxide-induced oxidative stress. Mutation Res. 2006;611:1-8.
71. Gargiulo P, Caccese D, Pignatelli P, et al. Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes Metabolism Res Revs. 2002;18:156-9.
72. Tessier D, Maheux P, Khalil A, Fulop T. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism. 1999;48:897-903.
73. Wiernsperger NF. Metformin: intrinsic vasculoprotective properties. Diabetes Technol Therap. 2000;2:259-72.
74. Mamputu JC, Wiernsperger NF, Renier G. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab. 2003;29:6S71-76.
75. Marquie G. Effect of metformin on lipid metabolism in the rabbit aortic wall. Atherosclerosis. 1978;30:165-70.
76. Marquie G. Metformin action on lipid metabolism in lesions of experimental aortic atherosclerosis of rabbits. Atherosclerosis. 1983;47:7-17.
77. Chakrabarti R, Hocking ED, Fearnley GR. Fibrinolytic effect of metformin in coronary artery disease. Lancet. 1965;II:256-9.
78. Hocking ED, Chakrabarti R, Evans J, Fearnley GR. Effects of biguanides and atromid on fibrinolysis. J Atheroscl Res. 1967;7:121-30.
79. Vague PH, Juhan-Vague I, Alessi MC, et al. Metformin decreases the high plasminogen activation inhibitor activity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemostasis. 1987;57:326-8.
80. Grant PJ, Strickl;and MH, Booth NA, Prentice CRM. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabetic Med. 1991;8:361-5.
81. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care. 1993;16:621-9.
82. Grant PJ. The effect of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 1996;19:64-6.
83. Grant PJ. Metformin reduces circulating factor VII concentrations in patients with type 2 diabetes mellitus. Thromb Haemostasis 1998;80:209.
84. He G, Pedersen SB, Bruun JM, et al. Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue. Horm Metab Res. 2003;35:18-23.
85. Standeven KF, Ariens RAS, Whitaker P, et al. The effect of dimethyl biguanide on thrombin activity FXIII activation, fibrin polymerization and fibrin clot formation. Diabetes. 2002;51:189-97.
86. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 2003;29:6S44-52.
87. Janka HU. Platelet and endothelial function tests during metformin treatment in diabetes mellitus. Horm Metab Res. 1985;12:120-2.
88. Gregorio F, Ambrosi F, Manfrini S. Poorly controlled elderly type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabetic Med. 1999;16:1016-24.
89. Weichert W, Breddin K. Antithrombotic effects of metformin in laser injured arteries. Diabetes Metab. 1988;14:540-43.
90. Massad L, Plotkine M, Allix M, Boulu RG. Antithrombic drugs in a carotid occlusion model: beneficial effect of the antidiabetic agent metformin. Diabetes Metab. 1988;14:544-48.
91. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258-68.
92. Diabetes Control and complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
93. Wiernsperger NF, Bouskela E. Microcirculation in insulin resistance and diabetes: more than just a complication. Diabetes Metab. 2003;29:6S77-87.
94. Tooke JE. Microvascular function in human diabetes: a physiological perspective. Diabetes. 1995;44:721-6.
95. Stansberry KB, Shapiro SA, Hill MA, et al. Impaired peripheral vasomotion in diabetes. Diabetes Care. 1996;19:715-21.
96. Sartoretto JL, Melo GA, Carvalho MH, et al. Metformin treatment restores the altered micro-vascular reactivity in neonatal streptozotocin-induced diabetic rats by increasing NOS activity, but not NOS expression. Life Sci. 2005;77:2676-89.
97. Rapin JR, Lespinasse P, Yoa R. Effect of metformin on diabetic erythrocyte deformability in the presence of insulin: in vitro study on erythrocytes from diabetic patients. Diabetes Metab. 1988;14:610-12.
98. Valensi P, Behar A, Andre P, et al. The effects of metformin on the capillary permeability to albumin in women patients with cyclic edema. Angiology. 1995;46:401-8.
99. Jyothirmayi GN, Soni BJ, Masurekar M, et al. Effects of metformin on collagen glycation and diastolic dysfunction in diabetic myocardium. J Cardiovasc Pharmacol Therap. 1998;3:319-26.